CytomX Therapeutics, Inc. (CTMX) awards 450,000 options and 100,000 RSUs to CLO
Rhea-AI Filing Summary
CytomX Therapeutics, Inc. granted Chief Legal Officer Alejandra Carvajal 450,000 stock options on August 3, 2026, with an exercise price of 3.1700 per share and expiration on August 2, 2036. The options vest 25% after one year from August 3, 2026, then monthly over four years, subject to continued service.
On the same date, Carvajal also received 100,000 restricted stock units (RSUs), each settling into one share of common stock upon vesting. These RSUs vest 25% annually each September 15, starting September 15, 2027, contingent on continued service. Following these awards, she holds 450,000 options and 100,000 RSUs directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 100,000 shares
Net Buy
2 txns
Insider
Carvajal Alejandra
Role
Chief Legal Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F3 | 450,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1, F2 | 100,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 450,000 shares (Direct);
Common Stock — 100,000 shares (Direct)
Footnotes (3)
- F1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on September 15 of each year, with the first 25% vesting on September 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such date.
- F2. Includes 100,000 RSUs.
- F3. 25% of the shares subject to the option vest on the one-year anniversary measured from August 3, 2026 (the "Vesting Commencement Date"), and 1/48 monthly thereafter such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
Key Figures
Stock options granted: 450000.0000 shares
Option exercise price: 3.1700 per share
Option expiration date: 2036-08-02
+5 more
8 metrics
Stock options granted
450000.0000 shares
Options granted to Chief Legal Officer on August 3, 2026
Option exercise price
3.1700 per share
Exercise price for 450,000 stock options
Option expiration date
2036-08-02
Expiration date of granted stock options
RSUs granted
100000.0000 units
Restricted stock units awarded on August 3, 2026
RSU first vesting date
September 15, 2027
First 25% of RSUs vest on this date
Post-award RSU holdings
100000.0000 units
Total RSUs held directly after the transaction
Post-award option holdings
450000.0000 shares
Total options held directly after the grant
Option vesting commencement
August 3, 2026
Date from which option vesting schedule is measured
Key Terms
restricted stock units ("RSUs"), Stock Option (Right to Buy), Vesting Commencement Date, Common Stock
4 terms
restricted stock units ("RSUs") financial
"Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Vesting Commencement Date financial
"measured from August 3, 2026 (the "Vesting Commencement Date")"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
Common Stock financial
"receive one (1) share of Common Stock for each RSU upon vesting"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What equity awards did CytomX (CTMX) grant to Chief Legal Officer Alejandra Carvajal?
CytomX granted Alejandra Carvajal 450,000 stock options and 100,000 RSUs on August 3, 2026. Each RSU converts into one common share upon vesting, and the options are exercisable for common stock at a fixed price per share.
What are the vesting terms of Alejandra Carvajal’s 100,000 RSUs at CytomX (CTMX)?
Carvajal’s 100,000 RSUs vest 25% annually on September 15 each year, starting September 15, 2027. Vesting is contingent on her continued service to CytomX through each vesting date, after which each RSU settles into one share of common stock.
How do the 450,000 stock options granted to CytomX (CTMX) CLO vest?
The 450,000 stock options vest 25% on the one-year anniversary of August 3, 2026, then 1/48 monthly so they are fully vested on the fourth anniversary. All vesting requires Carvajal’s continued service through each scheduled vesting date.
What is the exercise price and expiration date of Alejandra Carvajal’s CytomX (CTMX) stock options?
The stock options have an exercise price of 3.1700 per share and expire on August 2, 2036. Carvajal can exercise vested options any time before expiration, subject to plan terms and her continued service conditions outlined in the award.
Were Alejandra Carvajal’s CytomX (CTMX) equity grants made under a Rule 10b5-1 trading plan?
The Form 4 indicates the Rule 10b5-1 checkbox is not marked, so these equity awards are not reported as being made under a Rule 10b5-1 trading plan. They are characterized as grant/award acquisitions rather than open-market transactions.